--- a
+++ b/clusters/9knumclustersv2/clust_1352.txt
@@ -0,0 +1,44 @@
+Patients must not be known to be refractory to red blood cell or platelet transfusions
+Hemoglobin ?  g/dL with no blood transfusions (packed red blood cells and platelet transfusions) in the past  days, within  days prior to administration of study treatment
+Whole blood transfusions in the last  days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable
+Whole blood transfusions in the last  days prior to entry to the study which may interfere with gBRCA testing (packed red blood cells and platelet transfusions are acceptable)
+No platelet transfusions within  days of registration to meet eligibility criteria; Note: red blood cell transfusions are allowed at any time
+Transfusions are permitted to meet both the platelet and hemoglobin criteria; patients must not be known to be refractory to red blood cell or platelet transfusions
+Measured within  days prior to registration: hemoglobin >= . g/dL with no blood transfusions (packed red blood cells in the past  days is permitted)
+Whole blood transfusions in the last  days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable)
+Liver MRI (?  days prior to initiation of transplant conditioning) to document hepatic iron content is required for participants who are currently receiving ? packed red blood cell transfusions for ? year or have received ? packed red blood cell transfusions (cumulative). Participants who have hepatic iron content ? mg Fe/ g liver dry weight by liver MRI must have a liver biopsy and histological examination/documentation of the absence of cirrhosis, bridging fibrosis and active hepatitis (?  days prior to initiation of transplant conditioning).
+Blood (packed red blood cells, platelets) transfusions within  month prior to study start
+Unable to accept blood product transfusions
+Use of red blood cell or platelet transfusions within  weeks of treatment
+Within  days prior to registration: Hemoglobin >=  g/dL; patients may be transfused packed red blood cells (PRBCs) up to  week prior to when enrollment labs are drawn; on study, transfusions may be given as clinically indicated
+Patients who have had a whole blood transfusion within  days prior to enrollment. (Packed red blood cells and platelet transfusions are acceptable)
+Packed red blood cell transfusions or erythropoietin therapy within  days prior to the study enrollment unless erythropoietin therapy has been used to maintain a stable condition for at least  month prior to the enrollment
+Whole blood transfusions in the last  days prior to entry to the study
+Hematologic function, as follows (no red blood cell or platelet transfusions are allowed within  days of the first dose of enfortumab vedotin):
+Within two weeks prior to enrollment: Not refractory to red cell or platelet transfusions
+Patients should not be known to be refractory to red blood cell or platelet transfusions
+Whole blood transfusions in the last  days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable)
+Patients known to be refractory to platelet or packed red cell transfusions per Institutional Guidelines, or a patient who refuses blood product support.
+Patients must be willing to accept blood product transfusions
+Whole blood transfusions in the last  days
+Transfusion independent (no red blood cell or platelet transfusions in the preceding  weeks of screening)
+PHASE I: No blood transfusions  days prior to study entry
+PHASE II: No blood transfusions  days prior to study entry
+Patients refractory to red blood cell or platelet transfusions
+Whole blood transfusions in the last  days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable).
+Whole blood transfusions in the last  days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable)
+Whole blood transfusions in the last  days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable)
+Anemia that requires red blood cell transfusions
+Patients in CRi must have evidence of hematologic recovery after prior therapy independent of red blood cell transfusions
+blood transfusions prior to ,
+Whole blood transfusions in the last  days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable.
+Within  days after subjects signed the treatment consent: Hemoglobin >=  g/dl; patients may be transfused packed red blood cells (PRBCs) up to  week prior to when enrollment labs are drawn; on study, transfusions may be given as clinically indicated
+Unwilling to accept blood product transfusions
+Patients refractory to red blood cell or platelet transfusions
+Subject has received blood transfusions or hematopoietic factor therapy within  days prior to the first dose of study drug.
+Blood transfusions or hemopoietic factor therapy
+Patients with leukemia must not be known to be refractory to red blood cell or platelet transfusions.
+Any patient requiring chronic maintenance of red blood cell, white blood cell or granulocyte counts through the use of blood transfusions or growth factor support (e.g. Neulasta, Neupogen)
+Adequate renal, hepatic, and bone marrow function without frequent blood product or hematopoietic growth factor support (eg use of erythropoietin or transfusions >  units packed red blood cells every  months)
+Blood transfusions or hemopoietic factor therapy
+Platelet count >=  X ^/L w/o blood transfusions for  days preceding lab assessment, obtained within  days prior to PET scan